MEK162 in Combination With Capecitabine in Advanced Biliary Tract Cancer
Status:
Completed
Trial end date:
2019-01-07
Target enrollment:
Participant gender:
Summary
This study is to test the efficacy of MEK162 plus capecitabine in gemcitabine-pretreated
advanced biliary tract cancer, and to explore the predictive biomarkers for future
large-scale clinical trials using this combination.